Neurocrine Biosciences (NBIX) EPS (Basic) Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 15.17% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 3.18% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.42% |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 12.25% |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | -35.06% |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 13.47% |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 36.60% |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | -86.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.47% |
| Mar 31, 2026 | 65.05% |
| Dec 31, 2025 | 18.47% |
| Sep 30, 2025 | 43.38% |
| Jun 30, 2025 | 101.18% |
| Mar 31, 2025 | -18.40% |
| Dec 31, 2024 | 148.29% |
| Sep 30, 2024 | 75.48% |
| Jun 30, 2024 | 12.98% |
| Mar 31, 2024 | 8.47% |
| Dec 31, 2023 | -26.04% |
| Sep 30, 2023 | 50.00% |
| Jun 30, 2023 | 4.56% |
| Mar 31, 2023 | -58.12% |
| Dec 31, 2022 | 35.77% |
| Sep 30, 2022 | 6.89% |
| Jun 30, 2022 | -32.29% |
| Mar 31, 2022 | 28.67% |
| Dec 31, 2021 | -33.34% |
| Sep 30, 2021 | -24.88% |